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he Process of Bringing New
rug-Eluting Stents to Market
ill They See the Light of Day?*
avid R. Holmes, JR, MD, FACC,†
anesh Patel, MD‡
ochester, Minnesota; and Durham, North Carolina
he ZoMaxx stent (Abbott Laboratories, Abbott Park,
llinois) is a product that will likely never see the light of day
espite the performance of pilot human registry experiences
nd a randomized trial that enrolled 401 patients presented
n this issue of JACC: Cardiovascular Interventions (1). The
essons from an experience such as this have important
mplications that extend beyond the scope of this individual
rial. These lessons are derived from issues relating to
conomic and business considerations and trial design.
conomic and Business Issues
s is true with any proposed commercial product, the goal
f business is to provide shareholder value, service to the
ntended consumer, and a return on investment. In the
edical field, in this particular situation with drug-eluting
tents (DES), the considerations are complex—in part
See page 524
ecause of regulatory issues. These regulatory issues have
mportant implications for business decisions. Bringing a
omplex product such as a DES—in this case a trilayer
omposite with two outer layers of 316L stainless steel and
n inner layer of tantalum (which would have been very
aluable because it improves radio opacity); zotarolimus, a
rug specifically developed for use in DES without any
ther application; and a polymer drug carrier of phospho-
ylcholine—involves many hurdles. With the heightened
wareness of safety, specifically late and very late stent
hrombosis, and the need for longer term surveillance
ollow-up even after device approval, the costs of bringing a
ew stent to market have significantly increased. Some new
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.b
From the †Mayo Clinic, Rochester, Minnesota; and ‡Duke University, Durham,
orth Carolina.tents may never be marketed in the U.S. because of these
nancial and regulatory hurdles, even though these new
tents may have specific advantages such as improved
ide-branch access or better deliverability in tortuous arterial
egments. The ZoMaxx stent had potential advantages, as it
as designed to “address the need for thin stent width and
ow profile, while maintaining radial strength and adequate
isibility on fluoroscopy” (1).
At the same time, increasing numbers of stent technol-
gies have amplified the relative competition in the field.
ompetitive products deemed to have an advantage may
eapfrog other existing or developing technology. Given the
ong regulatory process, the field may change significantly
rom the point of product conception to device application,
uch that a “new” technology may be obsolete before it is
ver approved or fully adopted.
In the particular case of the ZoMaxx stent, after acquiring
nother company with a competitive DES, the manufac-
urer (Abbott Laboratories) apparently decided to shelve
his specific DES. That may be a real loss to the field
ecause of the potential advantages that this unique stent
ay have had in terms of deliverability and enhanced radio
pacity (related to the tantalum).
rial Design Issues
andomized trials demonstrating clinical benefit are the
oundation required for device approval and use. The
oMaxx trial was based upon the surrogate end point of late
umen loss. Surrogate end points are used with increasing
requency because they typically require smaller trial patient
opulation sizes and thus can be carried out more quickly
ith less cost. By definition, surrogates such as late loss
epresent only a part of the physiology and clinical effect of
device, and thus they have the potential disadvantage of
ot reflecting what the patient and clinicians are really
oncerned about, namely, clinical outcome such as death,
yocardial infarction, or repeat revascularizations.
Selection of late lumen loss in this trial as the primary end
oint was probably made in part based upon the results of
he intravascular ultrasound trial (2), which enrolled 40
atients in Brazil and which documented in-stent and
n-segment late lumen loss of 0.20  0.35 mm and 0.17 
.35 mm, respectively, at 4 months. The expectation of the
tudy investigators would have been that, compared with the
ell-described late loss with Taxus stents (3,4), this end
oint would be positive for the ZoMaxx stent. However, not
nly was the late lumen loss not favorable for the ZoMaxx
tent, it was even worse and statistically inferior. Of interest,
espite failing to meet preset noninferiority criteria, the
nvestigators spend considerable time and space discussing
n the manuscript why this is not relevant because a
retrospective analysis revealed that the inherent distur-
ances of normality, homogeneity, and similar shape were
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534ot met by either cohort” (1). Such post hoc retrospective
nalyses are not convincing for regulatory agencies or
onvested parties.
The reasons for the discrepancy between the pilot IVUS trial
esults may relate to differences in patient population and
ifferences in lesions treated. However, they also may relate
o late lumen loss being measured at 4 months in the pilot
tudy but not until 9 months in this current study. That raises
he possibility of late catch-up, which has now been docu-
ented with another DES (Xience, Abbott Laboratories) (5).
Yet another issue is the power calculation in these studies.
f interest in this study are 8 patients who reportedly had
n impact on outcome. These 8 patients had treatment of
stial lesions and by random chance were all in the ZoMaxx
tent group. In the final analyses, the presence of an ostial
esion in only 8 patients was the most significant multivar-
ate predictor of target vessel revascularization (p  0.002).
o have the development of a promising DES be decided in
art on the random occurrence of 8 patients is disturbing.
ad these patients been evenly distributed, the target lesion
evascularization rates might have been very different. In a
ighly competitive market, such small differences have great
mportance. The researchers conclude “that the efficacy of a
iven DES continues to be difficult to predict empirically, and
hat long-term comparative clinical testing of each new for-
ulation is required prior to its widespread application.” This
s certainly true with the proviso that trial design and power
alculations must be optimized.
The final issue of a comparator is also important. Should all
new” DES be required to be compared with currently avail-
ble DES? If so, which drug-eluting stent should be the
ontrol? Now with potentially 4 available DES, how are
nvestigators, clinicians, and patients to decide and evaluate
hese different comparisons? Possibilities include the newest Kpproved DES, the DES with the longest track record (that is
o say, the oldest one), or the newest bare-metal stent. Other
elated issues will be duration of follow-up and role of
ost-market surveillance to name but a few.
The ZoMaxx stent will presumably never see the light of
ay. In a time when the menu of DES in the pipeline
emains relatively limited, the loss of a product that might
ave substantial advantages is very real.
eprint requests and correspondence: Dr. David R. Holmes, Jr.,
ayo Clinic, Cardiovascular Diseases and Internal Medicine, 200
irst Street, SW, Rochester, Minnesota 55905. E-mail:
olmes.david@mayo.edu.
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